ORIC Pharmaceuticals, a clinical-stage oncology company focused on discovery and development of novel therapies against treatment-resistant cancers, announced yesterday that it has named Matt Panuwat as its new chief business officer.

Panuwat will serve on the executive leadership team and will lead business and corporate development for the company.

Prior to joining the company, Panuwat was senior vice president of Business Development at Prothena, where he led partnership activities and established the company's global research & development collaboration with Celgene. Prior to Prothena, he was head of Business Development at Medivation, where he led M&A and licensing activities, including the acquisition of talazoparib from BioMarin, until Medivation's acquisition by Pfizer. He was also earlier in corporate development at Questcor until its merger with Mallinckrodt, and spent nearly a decade in the Global Healthcare Investment Banking Group at Merrill Lynch.